The predictive value of liver tests for the presence of liver metastases.
breast neoplasms
colonic neoplasms
liver biochemical tests
liver metastases
lung neoplasms
malignant melanoma
Journal
Hepatic oncology
ISSN: 2045-0923
Titre abrégé: Hepat Oncol
Pays: England
ID NLM: 101629607
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
08
04
2023
accepted:
24
08
2023
medline:
27
10
2023
pubmed:
27
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
To analyze the predictive value of biochemical liver tests in patients with malignant melanoma, breast, colorectal or lung cancers at the time of diagnosis of liver metastases. A retrospective review of patients with the above-mentioned solid tumors at MedStar Georgetown University Hospital from 2016-2020. The highest optimal cutoff according to sensitivity and specificity for the presence of liver metastases was for AST ≥1.5 × ULN for melanoma, lung, and breast cancers and ≥2 × ULN for colorectal cancer, ALT ≥1.25 × ULN for melanoma, breast and colorectal cancers and ≥1.5 × ULN for lung cancer, and ALP ≥1.5 × ULN for melanoma, breast and colorectal cancers. Using thresholds of liver enzymes above the ULN may improve the diagnostic accuracy for the presence of liver metastases.
Identifiants
pubmed: 37885607
doi: 10.2217/hep-2023-0003
pmc: PMC10599222
doi:
Types de publication
Journal Article
Langues
eng
Pagination
HEP48Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
Conflicts of interests disclosure The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Références
Cancer. 2002 Nov 15;95(10):2044-50
pubmed: 12412156
J Clin Oncol. 2006 Nov 20;24(33):5313-27
pubmed: 17060676
Lancet Oncol. 2013 Nov;14(12):1208-15
pubmed: 24120480
Clin Exp Metastasis. 1992 May;10(3):191-9
pubmed: 1582089
HPB Surg. 1990;3(1):29-36; discussion 36-7
pubmed: 2090187
Oncol Lett. 2012 Oct;4(4):617-620
pubmed: 23205072
Gastroenterol Hepatol (N Y). 2011 Jan;7(1):62-5
pubmed: 21346857
Surg Oncol. 2013 Mar;22(1):36-47
pubmed: 23253399
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
pubmed: 2673568
Eur J Cancer. 2020 Dec;141:225-238
pubmed: 33189037
Ann Oncol. 2006 Apr;17(4):727
pubmed: 32521594
Breast Cancer. 2012 Jul;19(3):191-9
pubmed: 21567170
Oncotarget. 2016 Aug 23;7(34):55368-55376
pubmed: 27421135
Surg Oncol. 2007 Jul;16(1):3-5
pubmed: 17493802
Biomed Res Int. 2018 May 15;2018:9321270
pubmed: 29862297
Can Bull Med Hist. 2005;22(2):353-8
pubmed: 16482709
Cancer Biol Med. 2012 Mar;9(1):57-62
pubmed: 23691457
J Appl Res. 2005;5(1):88-95
pubmed: 19750205
Nat Rev Dis Primers. 2021 Apr 15;7(1):27
pubmed: 33859205
J Hepatol. 1999 Apr;30(4):726
pubmed: 10207817
J Clin Pathol. 1987 Apr;40(4):398-403
pubmed: 3584482
Mol Clin Oncol. 2015 Jan;3(1):217-221
pubmed: 25469298
Cancer Epidemiol. 2020 Aug;67:101760
pubmed: 32562887
CA Cancer J Clin. 1980 May-Jun;30(3):137-42
pubmed: 6769552
Ann Surg. 1984 May;199(5):502-8
pubmed: 6721600
JAMA. 1982 Sep 17;248(11):1329-32
pubmed: 7109154
World J Gastroenterol. 2010 Aug 28;16(32):4084-8
pubmed: 20731024
J Gastrointest Surg. 2007 Aug;11(8):1057-77
pubmed: 17530336
JAMA. 1979 Sep 14;242(11):1147-9
pubmed: 470066
J Am Coll Surg. 2014 Jul;219(1):62-8
pubmed: 24952441